abstract：PURPOSE:Rivaroxaban, an oral anticoagulant, undergoes the metabolism mediated by human cytochrome P450 (CYP). The present study is to quantitatively analyze and compare the contributions of multiple CYPs in the metabolism of rivaroxaban to provide new information for medication safety. METHODS:The metabolic stability ...

journal_title：Cardiovascular drugs and therapy

authors： Zhao T,Chen Y,Wang D,Wang L,Dong P,Zhao S,Wang C,Meng Q,Sun H,Liu K,Wu J

更新日期：2021-01-07 00:00:00

abstract：PURPOSE:To determine the association between low molecular weight heparin (LMWH) use and mortality in hospitalized COVID-19 patients. METHODS:We conducted a retrospective study of patients consecutively enrolled from two major academic hospitals exclusively for COVID-19 in Wuhan, China, from January 26, 2020, to March...

journal_title：Cardiovascular drugs and therapy

authors： Shen L,Qiu L,Liu D,Wang L,Huang H,Ge H,Xiao Y,Liu Y,Jin J,Liu X,Wang DW,Peterson ED,He B,Zhou N

更新日期：2021-01-04 00:00:00

abstract：PURPOSE:To assess the effects of electro-acupuncture (EA) on glycemic control, myocardial inflammation, and the progression of diabetic cardiomyopathy in mice with type 2 diabetes. METHODS:Db/Db mice received EA at PC6+ST36 (DM-Acu), non-acupoint simulation (DM-Sham), or no treatment (DM). EA was applied for 30 min pe...

journal_title：Cardiovascular drugs and therapy

authors： Ye Y,Birnbaum Y,Widen SG,Zhang Z,Zhu S,Bajaj M,Chen H

更新日期：2020-12-01 00:00:00

abstract：AIMS:Rapid restoration of sinus rhythm using pharmacological cardioversion is commonly indicated in patients with symptomatic recent-onset atrial fibrillation (AF). The objectives of this large, international, multicenter observational study were to determine the safety and effectiveness of intravenous (IV) vernakalant...

journal_title：Cardiovascular drugs and therapy

authors： Lévy S,Hartikainen J,Ritz B,Juhlin T,Carbajosa-Dalmau J,Domanovits H

更新日期：2020-11-18 00:00:00

abstract：PURPOSE:The ischemic/bleeding trade-off of continuing dual antiplatelet therapy (DAPT) beyond 1 year after PCI for patients with high thrombotic risk (HTR) as endorsed by 2018 ESC/EACTS myocardial revascularization guidelines remain unknown. METHODS:Patients undergoing coronary stenting between January 2013 and Decemb...

journal_title：Cardiovascular drugs and therapy

authors： Wang HY,Dou KF,Wang Y,Yin D,Xu B,Gao RL

更新日期：2020-10-01 00:00:00

abstract：PURPOSE:This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting. METHODS:We constructed a Markov model to project the lifetime direct medical costs and quality-adjusted life-years of both the...

journal_title：Cardiovascular drugs and therapy

authors： Lee MC,Liao CT,Toh HS,Chou CC,Chang WT,Chen ZC,Wu WS,Yu T,Strong C

更新日期：2020-09-10 00:00:00

abstract：PURPOSE:The glucose-lowering drug metformin has recently been shown to reduce myocardial oxygen consumption and increase myocardial efficiency in chronic heart failure (HF) patients without diabetes. However, it remains to be established whether these beneficial myocardial effects are associated with metformin-induced ...

journal_title：Cardiovascular drugs and therapy

authors： Larsen AH,Wiggers H,Dollerup OL,Jespersen NR,Hansson NH,Frøkiær J,Brøsen K,Nørrelund H,Bøtker HE,Møller N,Jessen N

更新日期：2020-08-08 00:00:00

abstract：BACKGROUND:Acute ST-elevation myocardial infarction (STEMI) is associated with a high incidence of complications as well as a considerable hospitalization rate and economic burden. Preliminary evidence suggests that remote ischemic conditioning (RIC) is a promising non-invasive intervention that may effectively and saf...

journal_title：Cardiovascular drugs and therapy

authors： Zheng Y,Reinhardt JD,Li J,Hu D,Lin S,Wang L,Dai R,Fan Z,Ding R,Chen L,Yuan L,Xu Z,Cheng Y,Yan C,Zhang X,Wang L,Zhang X,Teng M,Yu Q,Yin A,Lu X,i-RIC Trial Collaboration Group.

更新日期：2020-06-30 00:00:00

abstract：PURPOSE:Hypothyroidism (HT) is associated with accelerated atherosclerosis (AS). The efficacy of traditional strategies of hypothyroid AS remains controversial. Here, we aimed to deepen the understanding of the HT-induced acceleration of AS, to decrease the residual risk of coronary artery disease (CAD) and to find a n...

journal_title：Cardiovascular drugs and therapy

authors： Yang Y,Jia Y,Ning Y,Wen W,Qin Y,Zhang H,Du Y,Li L,Jiao X,Yang Y,Liu G,Huang M,Zhang M

更新日期：2020-06-03 00:00:00

abstract：BACKGROUND:The use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is currently expanding to cardiovascular risk reduction in non-diabetic subjects, but renal (side-)effects are less well studied in this setting. METHODS:Male non-diabetic Sprague Dawley rats underwent permanent coronary artery ligation to induc...

journal_title：Cardiovascular drugs and therapy

authors： Yurista SR,Silljé HHW,van Goor H,Hillebrands JL,Heerspink HJL,de Menezes Montenegro L,Oberdorf-Maass SU,de Boer RA,Westenbrink BD

更新日期：2020-06-01 00:00:00

abstract：PURPOSE:The melatonin receptor (MT) agonist ramelteon has a higher affinity to MT1 than for MT2 receptors and induces cardioprotection by involvement of mitochondrial potassium channels. Activation of mitochondrial potassium channels leads to release of free radicals. We investigated whether (1) ramelteon-induced cardi...

journal_title：Cardiovascular drugs and therapy

authors： Stroethoff M,Goetze L,Torregroza C,Bunte S,Raupach A,Heinen A,Mathes A,Hollmann MW,Huhn R

更新日期：2020-06-01 00:00:00

abstract：PURPOSE:This study tested if the protective anti-remodeling effect of GLP-1 agonist Exendin-4 after an acute myocardial infarction (MI) in rats involves inhibition of the Wnt1/β-catenin signaling pathway. METHODS:Rats were divided into sham, sham + Exendin-4 (10 μg/day, i.p), MI, and MI + Exendin-4. MI was introduced ...

journal_title：Cardiovascular drugs and therapy

authors： Eid RA,Khalil MA,Alkhateeb MA,Eleawa SM,Zaki MSA,El-Kott AF,Al-Shraim M,El-Sayed F,Eldeen MA,Bin-Meferij MM,Awaji KME,Shatoor AS

更新日期：2020-05-30 00:00:00

abstract：BACKGROUND:Heart failure (HF) is considered to be a prothrombotic condition and it has been suggested that coagulation factors contribute to maladaptive cardiac remodelling via activation of the protease-activated receptor 1 (PAR1). We tested the hypothesis that anticoagulation with the factor Xa (FXa) inhibitor apixab...

journal_title：Cardiovascular drugs and therapy

authors： Yurista SR,Silljé HHW,Nijholt KT,Dokter MM,van Veldhuisen DJ,de Boer RA,Westenbrink BD

更新日期：2020-05-26 00:00:00

abstract：BACKGROUND:Although Takotsubo syndrome (TS) was once considered to be rare and largely benign, it is now recognized to represent a major cause of cardiac morbidity and mortality, especially in ageing women. The biochemical precipitant of attacks of TS is an increase in catecholamine concentrations within the myocardium...

journal_title：Cardiovascular drugs and therapy

authors： Ong GJ,Nguyen TH,Stansborough J,Surikow SY,Horowitz JD

更新日期：2020-02-01 00:00:00

abstract：PURPOSE:Protein kinase C alpha (gene: PRKCA) is a key regulator of cardiac contractility. Two genetic variants have recently been discovered to regulate PRKCA expression in failing human heart tissue (rs9909004 [T → C] and rs9303504 [C → G]). The association of those variants with clinical outcomes in patients with hea...

journal_title：Cardiovascular drugs and therapy

authors： Luzum JA,Ting C,Peterson EL,Gui H,Shugg T,Williams LK,Li L,Sadee W,Wang D,Lanfear DE

更新日期：2019-12-01 00:00:00

abstract：:Pulmonary arterial hypertension is a rare disease, with drug-induced causes even more uncommon, accounting for only 10% of cases in large registry series. Predisposing factors for drug-induced PAH have not been completely defined. This review summarizes drugs with definite, possible, or likely association to pulmonary...

journal_title：Cardiovascular drugs and therapy

authors： Correale M,Tricarico L,Grazioli D,Formica ES,Petrucci R,Persichella P,Di Biase M,Brunetti ND

更新日期：2019-12-01 00:00:00

abstract：PURPOSE:To investigate the associations of diuretics overall, non-potassium-sparing diuretics in specific, and laxative use with cardiovascular mortality (CVM) in subjects with antihypertensive treatment. METHODS:Analyses included 4253 participants, aged 50 to 75 years, from the German ESTHER cohort and 105,359 partic...

journal_title：Cardiovascular drugs and therapy

authors： Hoppe LK,Muhlack DC,Koenig W,Brenner H,Schöttker B

更新日期：2019-10-01 00:00:00

abstract：PURPOSE:A multicentre, randomized, double-blind, placebo-controlled, parallel-group study aimed to define the potential positive effect of dipeptidyl peptidase-4 inhibition on left ventricular systolic function (LVSF) beyond glycemic control in type 2 diabetes mellitus (T2DM) (DYDA 2™ trial). METHODS:Individuals with ...

journal_title：Cardiovascular drugs and therapy

authors： Giorda CB,Cioffi G,Lucci D,Nada E,Ognibeni F,Mancusi C,Latini R,Maggioni AP,DYDA 2 Investigators.

更新日期：2019-10-01 00:00:00

abstract：PURPOSE:Treatment of pulmonary arterial hypertension (PAH) by vasodilator drug monotherapy is often limited in its effectiveness. Combination therapy may help to improve treatment and to reduce drug toxicity. This study assessed the combination of the endothelin receptor antagonist macitentan and the phosphodiesterase-...

journal_title：Cardiovascular drugs and therapy

authors： Hoenicka M,Golovchenko S,Englert L,Spaeth M,Shoshiashvili L,Großer C,Hofmann HS,Ried M

更新日期：2019-06-01 00:00:00

abstract：BACKGROUND:Clinical guidelines recommend peri-cardioversion anticoagulation in patients with atrial fibrillation (AF). We performed a systematic review and meta-analysis to compare the safety and efficacy of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with AF undergoing cardiovers...

journal_title：Cardiovascular drugs and therapy

authors： Gupta S,Um KJ,Pandey A,McIntyre WF,Ivanova M,Allahverdi Y,Agahi P,Pandya F,Lopez A,Sachdeva A,Whitlock RP,Belley-Cote EP

更新日期：2019-06-01 00:00:00

abstract：:High-density lipoprotein cholesterol (HDL-c) has long been referred to as 'good cholesterol' due to its apparent inverse relationship with future CVD risk. More recent research has questioned a causal role for HDL-c in this relationship, however, as both genetic studies and numerous large-scale randomised controlled t...

journal_title：Cardiovascular drugs and therapy

authors： Chiesa ST,Charakida M

更新日期：2019-04-01 00:00:00

abstract：:Cardiovascular disease is the leading cause of death in men and women in the USA. Once a patient experiences an acute coronary syndrome (ACS), they are at increased risk for hospital readmission within 30 days and 6 months after discharge and more importantly, they have worse survival. Hospital readmissions lead to po...

journal_title：Cardiovascular drugs and therapy

authors： Paruchuri V,Gaztanaga J,Rambhujun V,Smith R,Farkouh ME

更新日期：2018-12-01 00:00:00

abstract：PURPOSE:Ranolazine (RAN) added to amiodarone (AMIO) has been shown to accelerate termination of postoperative atrial fibrillation (POAF) following coronary artery bypass surgery in patients without heart failure (HF). This study aimed to investigate if treatment efficacy with AMIO or AMIO + RAN differs between patients...

journal_title：Cardiovascular drugs and therapy

authors： Simopoulos V,Hevas A,Hatziefthimiou A,Dipla K,Skoularigis I,Tsilimingas N,Aidonidis I

更新日期：2018-12-01 00:00:00

abstract：:The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; "320 mg twice a day" should read "160mg twice a day". The corrected paragraph is shown below. ...

journal_title：Cardiovascular drugs and therapy

authors： Ahn R,Prasad V

更新日期：2018-12-01 00:00:00

abstract：:Levosimendan, a calcium sensitizer and potassium channel-opener, is widely appreciated by many specialist heart failure practitioners for its effects on systemic and pulmonary hemodynamics and for the relief of symptoms of acute heart failure. The drug's impact on mortality in large randomized controlled trials has be...

journal_title：Cardiovascular drugs and therapy

authors： Bouchez S,Fedele F,Giannakoulas G,Gustafsson F,Harjola VP,Karason K,Kivikko M,von Lewinski D,Oliva F,Papp Z,Parissis J,Pollesello P,Pölzl G,Tschöpe C

更新日期：2018-12-01 00:00:00

abstract：PURPOSE:The prevalence and consequences of prediabetic dysglycemia and undiagnosed diabetes is unknown in patients with heart failure (HF) and preserved ejection fraction (HFpEF) and has not been compared to heart failure and reduced ejection fraction (HFrEF). METHODS:We examined the prevalence and outcomes associated...

journal_title：Cardiovascular drugs and therapy

authors： Kristensen SL,Jhund PS,Lee MMY,Køber L,Solomon SD,Granger CB,Yusuf S,Pfeffer MA,Swedberg K,McMurray JJV,CHARM Investigators and Committees.

更新日期：2017-12-01 00:00:00

abstract：PURPOSE:For patients with heart failure with reduced ejection fraction (HFrEF), guidelines recommend use of beta-blockers with gradual up-titration. However, many patients with HFrEF do not use beta-blockers and up-titration is rare. Our purpose was to identify and rank barriers to beta-blocker use and up-titration fro...

journal_title：Cardiovascular drugs and therapy

authors： Levitan EB,Van Dyke MK,Loop MS,O'Beirne R,Safford MM

更新日期：2017-12-01 00:00:00

abstract：PURPOSE:The need for novel approaches to cardiovascular drug development served as the impetus to convene an open meeting of experts from the pharmaceutical industry and academia to assess the challenges and develop solutions for drug discovery in cardiovascular disease. METHODS:The Novel Cardiovascular Therapeutics S...

journal_title：Cardiovascular drugs and therapy

authors： Povsic TJ,Scott R,Mahaffey KW,Blaustein R,Edelberg JM,Lefkowitz MP,Solomon SD,Fox JC,Healy KE,Khakoo AY,Losordo DW,Malik FI,Monia BP,Montgomery RL,Riesmeyer J,Schwartz GG,Zelenkofske SL,Wu JC,Wasserman SM,Roe MT

更新日期：2017-08-01 00:00:00

abstract：PURPOSE:The mitogen-activated protein kinase phosphatases (MKPs) are a family of dual-specificity phosphatases that inactivate MAPKs by dephosphorylation. Impairment of MKP-1 expression in insulin resistance has been suggested to affect the cardioprotective properties of insulin. We hypothesized that manipulation of it...

journal_title：Cardiovascular drugs and therapy

authors： Webster I,Smith A,Lochner A,Huisamen B

更新日期：2017-06-01 00:00:00

abstract：PURPOSE:Morphine has been used for several decades in cases of acute pulmonary edema (APE) due to the anxiolytic and vasodilatory properties of the drug. The non-specific depression of the central nervous system is probably the most significant factor for the changes in hemodynamics in APE. Retrospective studies have s...

journal_title：Cardiovascular drugs and therapy

authors： Dominguez-Rodriguez A,Burillo-Putze G,Garcia-Saiz MDM,Aldea-Perona A,Harmand MG,Mirò O,Abreu-Gonzalez P,MIMO investigators.

更新日期：2017-04-01 00:00:00

abstract：:Mitochondrial health is critically dependent on the ability of mitochondria to undergo changes in mitochondrial morphology, a process which is regulated by mitochondrial shaping proteins. Mitochondria undergo fission to generate fragmented discrete organelles, a process which is mediated by the mitochondrial fission p...

journal_title：Cardiovascular drugs and therapy

authors： Ong SB,Kalkhoran SB,Hernández-Reséndiz S,Samangouei P,Ong SG,Hausenloy DJ

更新日期：2017-02-01 00:00:00

abstract：RATIONALE:Pulmonary hypertension (PH) represents a serious health complication accompanied with hypoxic conditions, elevated levels of asymmetric dimethylarginine (ADMA), and overall dysfunction of pulmonary vascular endothelium. Since the prevention strategies for treatment of PH remain largely unknown, our study aime...

journal_title：Cardiovascular drugs and therapy

authors： Koudelka A,Ambrozova G,Klinke A,Fidlerova T,Martiskova H,Kuchta R,Rudolph TK,Kadlec J,Kuchtova Z,Woodcock SR,Freeman BA,Kubala L,Pekarova M

更新日期：2016-12-01 00:00:00

abstract：:Despite continuous advances in myocardial revascularization procedures and intracoronary devices, patients with ischemic heart disease (IHD) still experience worse prognosis and poor quality of life (QoL). Indeed, chronic stable angina (CSA) is a common disease with a large burden on healthcare costs. Traditionally, C...

journal_title：Cardiovascular drugs and therapy

authors： Guarini G,Huqi A,Morrone D,Marzilli M

更新日期：2016-08-01 00:00:00

abstract：PURPOSE:To evaluate whether aleglitazar (Ale), a dual PPARα/γ agonist, has additive effects on myocardial protection against ischemia-reperfusion injury. METHODS:Human cardiomyocytes (HCMs), cardiomyocytes from cardiac-specific PPARγ knockout (MCM-PPARγ (CKO) ) or wild type (MCM-WT) mice were incubated with different ...

journal_title：Cardiovascular drugs and therapy

authors： Qian J,Chen H,Birnbaum Y,Nanhwan MK,Bajaj M,Ye Y

更新日期：2016-04-01 00:00:00

abstract：:Investment in cardiovascular drug development is on the decline as large cardiovascular outcomes trials require considerable investments in time, efforts and financial resources. Pharmacogenomics has the potential to help revive the cardiovascular drug development pipeline by providing new and better drug targets at a...

journal_title：Cardiovascular drugs and therapy

authors： Dubé MP,de Denus S,Tardif JC

更新日期：2016-02-01 00:00:00

abstract：:In both epidemiologic and genetic studies, increased levels of Lp(a) have been associated with increased risk for cardiovascular diseases as well as aortic stenosis. However, until recently, it has been difficult to lower levels of Lp(a). Diet and lifestyle have little effect on plasma levels of Lp(a) which are mainly...

journal_title：Cardiovascular drugs and therapy

authors： Stein EA,Raal F

更新日期：2016-02-01 00:00:00

abstract：PURPOSE:Epidemiologic and clinical research suggests important gender-related differences in the prevalence, presentation, associated conventional and non-conventional risk factors, management and outcomes of coronary heart disease (CHD) patients. Adequate data is not available for Indian population where prevalence of...

journal_title：Cardiovascular drugs and therapy

authors： Bhatt P,Parikh P,Patel A,Parikh R,Patel A,Mehta JL,Parikh K

更新日期：2015-08-01 00:00:00

abstract：:In the latter half of the 20th century, among participants of the Framingham Heart Study, incidence of heart failure (HF) has declined by about a third in women but not in men and survival after the onset of HF has improved in both sexes; however, HF remains highly lethal with over 50% dying within 5 years after onset...

journal_title：Cardiovascular drugs and therapy

authors： Kenchaiah S,Vasan RS

更新日期：2015-08-01 00:00:00

abstract：PURPOSE:The glucagon-like peptide-1 (GLP-1) has been shown to exert cardioprotective effects in animals and patients. This study tests the hypothesis that preservation of GLP-1 by the GLP-1 receptor agonist liraglutide or the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is associated with a reduction of angiote...

journal_title：Cardiovascular drugs and therapy

authors： Zhang LH,Pang XF,Bai F,Wang NP,Shah AI,McKallip RJ,Li XW,Wang X,Zhao ZQ

更新日期：2015-06-01 00:00:00

abstract：PURPOSE:Mechanical stretch is an arrhythmogenic factor found in situations of cardiac overload or dyssynchronic contraction. Ranolazine is an antianginal agent that inhibits the late Na (+) current and has been shown to exert a protective effect against arrhythmias. The present study aims to determine whether ranolazin...

journal_title：Cardiovascular drugs and therapy

authors： Chorro FJ,del Canto I,Brines L,Such-Miquel L,Calvo C,Soler C,Parra G,Zarzoso M,Trapero I,Tormos Á,Alberola A,Such L

更新日期：2015-06-01 00:00:00